David W. Meyer

SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

May S.K. Sutherland, Roland B. Walter, Scott C. Jeffrey et al. · Blood · 2013 · 381 citations

A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology

Scott C. Jeffrey, Patrick Burke, Robert P. Lyon et al. · Bioconjugate Chemistry · 2013 · 241 citations

Drug Target, Immunology, Molecular Biology +21

Novel Peptide Linkers for Highly Potent Antibody−Auristatin Conjugate

Svetlana O. Doronina, Tim D. Bovee, David W. Meyer et al. · Bioconjugate Chemistry · 2008 · 171 citations

Peptide Engineering, Immunology, Peptide Science +17

Sequence and submolecular localization of the 115-kD accessory subunit of the heterotrimeric kinesin-II (KRP85/95) complex.

Karen P. Wedaman, David W. Meyer, Dana J. Rashid et al. · The Journal of Cell Biology · 1996 · 145 citations · Full text

Heterotrimeric Kinesin-ii, Protein Assembly, Structural Bioinformatics +17

Design, Synthesis, and Biological Evaluation of Antibody−Drug Conjugates Comprised of Potent Camptothecin Analogues

Patrick Burke, Peter D. Senter, David W. Meyer et al. · Bioconjugate Chemistry · 2009 · 109 citations